US EditionWhat's Going On With AstraZeneca Stock Tuesday? - AstraZeneca (NASDAQ:AZN)
Baxdrostat, an aldosterone synthase inhibitor, significantly reduced systolic blood pressure by nearly 10 mmHg placebo-adjusted in patients with hard-to-control hypertension in a global Phase III trial.
- Professor Bryan Williams led the international BaxHTN Phase III trial sponsored by AstraZeneca, presenting results on August 30, 2025, at the ESC Congress in Madrid.
- The trial enrolled nearly 800 adults with uncontrolled or treatment-resistant hypertension despite standard therapy, lasting 12 weeks with patients taking 1 mg or 2 mg baxdrostat tablets daily.
- Baxdrostat significantly lowered systolic blood pressure by about 9 to 10 mmHg more than placebo and nearly 40% of patients achieved the target below 130 mmHg versus fewer than 20% on placebo.
- Professor Williams highlighted the promising results from the BaxHTN Phase III trial, emphasizing that baxdrostat produced an approximate 10 mmHg decrease in systolic blood pressure, a change associated with a significantly reduced risk of cardiovascular events and kidney complications.
- Baxdrostat showed a favorable safety profile with mostly mild adverse events, low hyperkalaemia rates of 1.1%, no unanticipated findings, and offers hope for effective treatment of resistant hypertension globally.
11 Articles
11 Articles
Baxdrostat offers hope for millions with difficult-to-control high blood pressure
A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III clinical trial led by a UCL Professor.
Scientists reveal breakthrough blood pressure treatment that works when others fail
A breakthrough pill, baxdrostat, has shown remarkable success in lowering dangerously high blood pressure in patients resistant to standard treatments. In a large international trial, it cut systolic pressure by nearly 10 mmHg, enough to significantly reduce risks of heart attack, stroke, and kidney disease. The drug works by blocking excess aldosterone, a hormone that drives uncontrolled hypertension.
Baxdrostat ‘a potential game changer’ for treatment-resistant hypertension
Adding baxdrostat to background antihypertensive therapy led to substantial reductions in seated systolic blood pressure after 12 weeks of treatment among patients with uncontrolled or resistant hypertension.The results of the phase 3, multinational, double-blind, randomized, placebo-controlled BaxHTN trial of baxdrostat (AstraZeneca), an aldosterone synthase inhibitor, in patients with
MedPage Today
Anti-Aging, Acupuncture and Health NewsNovel Antihypertensive Effective for Uncontrolled, Resistant Hypertension
(MedPage Today) -- MADRID -- For uncontrolled or treatment-resistant hypertension, adding the novel aldosterone synthase inhibitor baxdrostat improved blood pressure in the randomized BaxHTN trial. Seated systolic blood pressure improved by...
Coverage Details
Bias Distribution
- 83% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
